Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists

Regorafenib (BAY 73-4506, Stivarga® Bayer HealthCare Pharmaceutical Inc) is an oral multikinase inhibitor with a distinct and wide-ranging profile of tyrosine kinase inhibition, resulting in antiangiogenic and antiproliferative properties in tumors. Single-agent regorafenib administered as a 160-mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Rey, Jean-Baptiste, Launay-Vacher, Vincent, Tournigand, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4457933/
https://www.ncbi.nlm.nih.gov/pubmed/25213039
http://dx.doi.org/10.1007/s11523-014-0333-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4457933/
https://www.ncbi.nlm.nih.gov/pubmed/25213039
http://dx.doi.org/10.1007/s11523-014-0333-x

Ejemplares similares